Brandes Investment Partners LP Sells 1,737,653 Shares of Elanco Animal Health Incorporated $ELAN

Brandes Investment Partners LP cut its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 29.3% in the fourth quarter, Holdings Channel reports. The fund owned 4,201,864 shares of the company’s stock after selling 1,737,653 shares during the period. Brandes Investment Partners LP’s holdings in Elanco Animal Health were worth $95,088,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. State of Michigan Retirement System bought a new position in shares of Elanco Animal Health during the third quarter valued at $2,383,000. Teachers Retirement System of The State of Kentucky bought a new position in shares of Elanco Animal Health during the third quarter valued at $2,215,000. JPMorgan Chase & Co. lifted its holdings in shares of Elanco Animal Health by 266.4% during the third quarter. JPMorgan Chase & Co. now owns 1,918,336 shares of the company’s stock valued at $38,635,000 after acquiring an additional 1,394,839 shares during the period. Royce & Associates LP lifted its holdings in shares of Elanco Animal Health by 21.3% during the third quarter. Royce & Associates LP now owns 602,564 shares of the company’s stock valued at $12,136,000 after acquiring an additional 105,632 shares during the period. Finally, Ameritas Investment Partners Inc. bought a new position in shares of Elanco Animal Health in the third quarter valued at about $1,876,000. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Stock Performance

Elanco Animal Health stock opened at $24.48 on Wednesday. The stock has a 50-day simple moving average of $22.89 and a 200 day simple moving average of $23.44. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $12.23 billion, a price-to-earnings ratio of -48.97, a P/E/G ratio of 1.55 and a beta of 1.69. Elanco Animal Health Incorporated has a 12-month low of $13.15 and a 12-month high of $27.72.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. The firm had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company’s revenue was up 14.9% on a year-over-year basis. During the same period last year, the company earned $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, research analysts anticipate that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ELAN. JPMorgan Chase & Co. lifted their price target on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Citigroup lifted their price target on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, May 7th. UBS Group reaffirmed a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Weiss Ratings cut Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. Finally, Morgan Stanley lifted their price target on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a report on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $28.20.

Insider Transactions at Elanco Animal Health

In other news, insider Rajeev A. Modi acquired 4,911 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the transaction, the insider directly owned 160,812 shares in the company, valued at $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jeffrey N. Simmons acquired 4,971 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average price of $20.09 per share, with a total value of $99,867.39. Following the completion of the transaction, the chief executive officer owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 1.14% of the stock is owned by company insiders.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.